Delivery Order SPE2DB24D6044-SPE2DB25FLHHQ

Award Date 1/28/25
Potential Completion Date 1/29/25
Potential Value $6.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a major pharmaceutical distributor, a $17,976.09 firm-fixed-price delivery order contract for 4,563,079,908 units of the drug Valsartan-HCTZ 320-25 mg tablets. This order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,943,211 units of Valsartan-HCTZ 320-12.5 mg tablets in packages of 90. The contract has a ceiling value of $10,255.95 and a period of performance through March 13, 2024. Amerisourcebergen Drug Corp is the prime contractor and holds an indefinite delivery contract (IDC) with DLA valued at up to $999,999,999...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded Amerisourcebergen Drug Corp's Corporate Office Division a $4,590.37 firm-fixed-price delivery order contract (SPE2DX15D3108|SPE2DX24F27HA) for the supply of 90-count valsartan-hydrochlorothiazide 80-12.5 mg tablets. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 through December 2025, which enables the DLA to efficiently procure a comprehensive range of pharmaceutical and...
This is a $3,615.46 delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Valsartan-HCTZ 160-12.5 mg tablets in 90-count packages. The contract has an ultimate completion date of March 12, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support...
The U.S. Defense Logistics Agency (DLA) awarded a $2,418.49 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp for the supply of 4,565,242,865 units of the pharmaceutical product Valsartan-HCTZ 160-25 mg tablets in 90-count packages. The contract has an ultimate completion date of July 25, 2024. This contract is not set aside for any specific business category. AmerisourceBergen, a major pharmaceutical distributor, has been awarded numerous Indefinite Delivery Contracts...
This federal contract was awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation's Corporate Office division. The $1,303.74 firm-fixed-price delivery order is for the supply of 90 units of the pharmaceutical product Valsartan-HCTZ 320-25 mg tablets. The contract has an ultimate completion date of August 15, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,563,154,096 units of the drug Valsartan-HCTZ 160-12.5 mg tablets. The firm-fixed-price delivery order contract has a ceiling value of $4,156.30 and a completion date of December 21, 2023. This award is not designated as a set-aside contract. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $2,018.59 firm-fixed-price delivery order is for the supply of Valsartan-HCTZ 320-25 mg tablets in 90-count bottles. The contract has an ultimate completion date of August 9, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $19,858.67, is for the supply of Valsartan-HCTZ 160-12.5 mg tablets in 90-count bottles. The award has an ultimate completion date of January 31, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Valsartan-HCTZ 320-25 mg tablets. The $7,553.52 delivery order was awarded as a firm fixed price contract, with an ultimate completion date of September 3, 2024. This order is likely part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at up to $999,999,999...
  • SPE2DB24D6044
    Indefinite Delivery Contract
  • SPE2DB24D6044-SPE2DB25FLHHQ
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a $6,894.05 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,567,062,501 units of Valsartan-HCTZ 320-12.5 mg tablets. The contract has an ultimate completion date of January 29, 2025. This contract is part of AmerisourceBergen's larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 4/29/25, 9:55 AM